There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Chicago yesterday. The study looked at Merck & Co's Keytruda as a fi
At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastati
At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase III studies, but the future is also here. Early phase I and II trials that test
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
